Pentixapharm Holding AG is a Germany-based clinical-stage radiopharmaceutical development company. The Company focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. It is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
22/09/26	€1.900	+0.53%	19,497
21/09/26	€1.890	-0.53%	17,952
18/09/26	€1.900	+1.33%	976
17/09/26	€1.875	+1.90%	2,109
16/09/26	€1.840	-3.16%	8,532

Delayed Quote Xetra

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.900EUR

Average target price

9.265EUR

Spread / Average Target

+387.63%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Xetra 19:35:31 22/09/2026 +04			5-day change	1st Jan Change
1.900 ^EUR	+0.53%		0.00%	+28.21%

08-06	Pentixapharm Holding AG Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-06	Pentixapharm Holding AG and Pentixapharm AG Announce Executive Changes	CI

Market Cap	47.09M 53.88M 44.26M 40.39M 75.8M 5.15B 75.81M 531M 205M 2.63B 202M 198M 8.48B	P/E 2026 *	-3.06x	P/E 2027 *	-2.88x
Enterprise Value	39.79M 45.53M 37.4M 34.13M 64.05M 4.35B 64.06M 449M 173M 2.22B 171M 167M 7.17B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	68.98%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Xetra	PTP	Delayed
Tradegate	PTP	Real-time
CBOE		Real-time
Börse Stuttgart	PTP	Delayed
Boerse Muenchen	PTP	Real-time
Deutsche Boerse AG	PTP	Delayed
CBOE		Real-time
Wiener Boerse	PTPN	End-of-day quote

08-06	Pentixapharm Holding AG Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-06	Pentixapharm Holding AG and Pentixapharm AG Announce Executive Changes	CI
08-06	Pentixapharm Holding Ag Reaffirms Earnings Guidance for the Full Year 2026	CI
07-22	Pentixapharm Raises EUR16.8 Million via Rights Offering	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-22	Eckert & Ziegler next in BaFin's sights, shares rebound	DP
07-22	Eckert & Ziegler Faces BaFin Review Over Pentixapharm Spin-off Accounting	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-09	Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary Aldosteronism	CI
07-09	Pentixapharm's Underdevelopment Radiodiagnostic Gets Fast Track Designation From US FDA	MT
06-09	Pentixapharm Disputes German Regulator's Preliminary Error Findings in FY24 Financial Statements	MT
06-09	Pentixapharm Holding Ag Announces Fda Clearance of Ind for Phase 3 Panda Study of First-In-Class Cardiovascular Diagnostic Program	CI
06-09	Pentixapharm Gains US FDA Clearance for Late-stage PentixaFor Study	MT

Pentixapharm Holding AG Stock

Stocks

PTP

DE000A40AEG0

Pharmaceuticals

Valuation: Pentixapharm Holding AG

Chart: Pentixapharm Holding AG

Latest news: Pentixapharm Holding AG

Press Releases: Pentixapharm Holding AG

News in other languages: Pentixapharm Holding AG

Quotes and Performance

Price Extremes

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

08-17	Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Purchase of shares by exercising subscription rights	EQ
08-06	Pentixapharm Reports Second Quarter and First Half 2026 Results and Advances Phase 3 Panda Program	EQ
07-27	Pentixapharm Completes Capital Increase – New Shares Placed in Full	EQ
07-27	Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today	EQ
07-23	Pentixapharm Holding AG - Ad-hoc, Rights offering successfully completed, Remaining shares can be subscribed for via private placement	AQ

1 day	+0.53%
Current month	+2.70%
1 month	-0.26%
3 months	-6.40%
6 months	+2.93%
Current year	+28.21%

1 week	1.84	1.91
1 month	1.81	1.92
Current year	1.48	3.7
1 year	1.3	3.7
3 years	1.3	5.15
5 years	1.3	5.15
10 years	1.3	5.15

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/07/26	Andreas Eckert	Exercice	Chairman	3,965,539	11.0721%
07/07/26	Andreas Eckert	Free	Chairman	8,922,464	35.9842%
27/11/25	Andreas Eckert	Buy	Chairman	70,924	0.2860%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PENTIXAPHARM HOLDING AG	+0.53%	0.00%	+1.06%	-	53.88M
ELI LILLY AND COMPANY	+0.45%	+3.00%	+55.00%	+112.54%	1,043B
JOHNSON & JOHNSON	-0.10%	+0.74%	+54.52%	+67.72%	649B
ABBVIE INC.	+0.28%	+0.82%	+19.15%	+73.63%	469B
ROCHE HOLDING AG	-0.19%	+0.97%	+34.30%	+45.99%	355B
NOVARTIS AG	+0.28%	+2.30%	+18.47%	+26.67%	270B
ASTRAZENECA PLC	+0.89%	+4.59%	+10.19%	+14.72%	262B
AMGEN INC.	+4.34%	+9.21%	+43.44%	+53.25%	222B
GILEAD SCIENCES, INC.	+1.40%	+4.35%	+35.72%	+103.53%	189B
NOVO NORDISK A/S	-0.46%	-6.20%	-32.46%	-59.65%	175B
Average	+0.71%	+1.83%	+23.94%	+48.71%	363.31B
Weighted average by Cap.	+0.49%	+2.10%	+36.40%	+67.20%

	2026 *	2027 *
Net sales	-	-
Net income	-22.3M -25.52M -20.96M -19.13M -35.9M -2.44B -35.9M -252M -97.06M -1.25B -95.83M -93.73M -4.02B	-23.5M -26.89M -22.09M -20.16M -37.83M -2.57B -37.84M -265M -102M -1.31B -101M -98.77M -4.23B
Net Debt	-7.3M -8.35M -6.86M -6.26M -11.75M -799M -11.75M -82.34M -31.77M -408M -31.37M -30.68M -1.31B	12.3M 14.07M 11.56M 10.55M 19.8M 1.35B 19.8M 139M 53.54M 687M 52.86M 51.7M 2.22B